Abbott Hosts Conference Call for Fourth-Quarter Earnings

1/3/24 9:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ABT alert in real time by email

ABBOTT PARK, Ill., Jan. 3, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2023 financial results on Wednesday, Jan. 24, before the market opens.

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

View original content:https://www.prnewswire.com/news-releases/abbott-hosts-conference-call-for-fourth-quarter-earnings-302024803.html

SOURCE Abbott

Get the next $ABT alert in real time by email

Date	Price Target	Rating	Analyst
10/8/2024	$130.00	Outperform	Oppenheimer
9/19/2024	$131.00	Overweight	Piper Sandler
7/30/2024		Buy → Hold	Edward Jones
5/30/2024	$121.00	Buy	Goldman
7/21/2023		Underperform → Peer Perform	Wolfe Research
5/30/2023	$112.00	Overweight → Equal-Weight	Morgan Stanley
4/20/2023	$125.00 → $127.00	Overweight	Barclays
4/20/2023	$107.00 → $103.00	Underperform	Wolfe Research

Abbott Hosts Conference Call for Fourth-Quarter Earnings

Chat with this insight

Recent Analyst Ratings for $ABT

$ABT SEC Filings

Abbott Laboratories filed SEC Form 8-K: Leadership Update

SEC Form 10-Q filed by Abbott Laboratories

Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ABT Press Releases

Fastest customizable press release news feed in the world

New Canadian Report Shows Positivity Instead of Criticism is Key in Diabetes Management

Seamless Data: Tidepool and Abbott's New Cloud-to-Cloud Integration Partnership

Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure

$ABT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Oppenheimer initiated coverage on Abbott Labs with a new price target

Piper Sandler initiated coverage on Abbott Labs with a new price target

Abbott Labs downgraded by Edward Jones

$ABT Market Insights

Live Market Insights

Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers

Dow Plunges Over 500 Points Following Unexpected Surge In US Jobless Claims

Why Are Abbott Laboratories Shares Trading Lower?

$ABT Financials

Live finance-specific insights

Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range

Abbott Hosts Conference Call for Third-Quarter Earnings

Abbott Declares 403rd Consecutive Quarterly Dividend

$ABT Large Ownership Changes

This live feed shows all institutional transactions in real time.

$ABT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

EXECUTIVE VICE PRESIDENT Allen Hubert L exercised 157,421 units of Common shares without par value at a strike of $47.00 and sold $18,424,298 worth of Common shares without par value (157,421 units at $117.04) (SEC Form 4)

SEC Form 4 filed by Director Stratton John G

SEC Form 4 filed by Director Roman Michael F

$ABT FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

$ABT Leadership Updates

Live Leadership Updates

Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

BioSig Technologies, Inc. Appoints John Sieckhaus as Chief Operating Officer

ACELYRIN Appoints Melanie Gloria as Chief Operating Officer

Recent Analyst Ratings for
$ABT

$ABT
SEC Filings

$ABT
Press Releases

$ABT
Analyst Ratings

$ABT
Market Insights

$ABT
Financials

$ABT
Large Ownership Changes

$ABT
Insider Trading

$ABT
FDA approvals

$ABT
Leadership Updates